MC
BMRN icon

Moors & Cabot’s BioMarin Pharmaceuticals BMRN Stock Holding History

Moors & Cabot’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,450
Closed -$284K – 878
2024
Q2 		$284K Sell
3,450
-20
-0.6% -$1.67K 0.02% 644
2024
Q1 		$303K Buy
3,470
+482
+16% +$43.1K 0.02% 665
2023
Q4 		$288K Buy
2,988
+22
+0.7% +$1.95K 0.02% 636
2023
Q3 		$262K Sell
2,966
-1,298
-30% -$115K 0.02% 638
2023
Q2 		$370K Sell
4,264
-199
-4% -$18.7K 0.02% 540
2023
Q1 		$434K Buy
4,463
+33
+0.7% +$3.42K 0.03% 477
2022
Q4 		$458K Sell
4,430
-37
-0.8% -$3.47K 0.03% 452
2022
Q3 		$379K Sell
4,467
-1,305
-23% -$116K 0.03% 483
2022
Q2 		$478K Hold
5,772
– – 0.03% 427
2022
Q1 		$445K Sell
5,772
-63
-1% -$5.27K 0.03% 501
2021
Q4 		$516K Buy
5,835
+1,200
+26% +$99K 0.03% 453
2021
Q3 		$357K Buy
4,635
+205
+5% +$16.2K 0.02% 541
2021
Q2 		$370K Buy
+4,430
New +$351K 0.03% 504
2015
Q2 		– Sell
-2,158
Closed -$266K – 528
2015
Q1 		$266K Buy
+2,158
New +$229K 0.04% 408

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Moors & Cabot's BMRN Position: Q3 2024 in Review

Moors & Cabot sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 3,450 shares — an estimated $284K sold.

Moors & Cabot first reported a position in BMRN in Q1 2015 and held it in 14 quarters. The position peaked at $516K in Q4 2021. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • Moors & Cabot reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Moors & Cabot sold 3,450 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $284K.
  • Moors & Cabot first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 14 quarters.
  • Moors & Cabot's BioMarin Pharmaceuticals position peaked at $516K in Q4 2021.
  • 553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Moors & Cabot's 13F filing for Q3 2024, filed 8 Nov 2024.